ICCPP ODM+ Won Two Muse Design Gold Awards, Keeping Leading the Creative Design Trend
15.9.2023 15:00:00 EEST | Business Wire | Press release
Recently, the winners of MUSE Design Awards 2023, known as the Oscar Awards of the design, were announced, and ICCPP ODM+'s Cyclo eco-friendly e-cigarette and SPEEX X1, one of SPEEX dual-coils and screen display series display products, stood out and won Gold Awards of Muse Design from nearly 40,000 works worldwide, thanks to their advanced globalization vision, innovative user-centered design, and sustainable concepts of caring for both human beings and nature.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230904756304/en/
ICCPP ODM+ Won MUSE DESIGN GOLD AWARDS (Photo: Business Wire)
MUSE Design Awards was founded in 2015 by International Awards Associates (IAA), a long-established U.S.-based international design awards association, and is one of the most influential international awards in the field of global creative design. The awards have always been known for their rigorous judging system and high quality standards, aiming to cultivate, promote and recognize excellence in the global design field, and promote the development of the global design industry to a higher level.
ICCPP ODM+ won the two design gold awards in one go in its first competition, which was not only a confirmation of its global leadership in future-oriented innovative product design, concepts and inspirations, but also a recognition of the strength of ICCPP Group's user-centered approach to deepening innovation and empowering the development of the e-atomization industry, and even set a new benchmark for global brands in e-cigarette product design.
It is understood that one of the Gold Award winners, SPEEX X1 is an independent innovative flagship product of the SPEEX heating technology series with high-capacity, dual coil and screen display from ICCPP ODM+, listed in August. It is a unique combination of dual-coil design with dual output working models and SPEEX rocket-like heating technology, and plus the small, rounded, extremely compact and aesthetic design, superimposed on the 0.73-inch oversized e-liquid and power remain screen display, SPEEX X1 achieves a perfect balance among the flavor, vapor, aesthetics and user thinking.
Cyclo, the other winner of Muse Design Gold Awards, is a new 2ml product launched by ICCPP ODM+ at VAPER EXPO UK2023 in May. Considering global trend of low carbon and environmentally friendly concept, coupled with the deep concerns of global users about increasingly serious environmental problems caused by the prevalence of disposable e-cigarettes, as well as the enforce reality of Europe's new Battery Law and some environmental protection acts, ICCPP ODM+ innovatively developed Cyclo, the world's first double environmentally-friendly concept disposable e-cigarettes solution. Through its innovative application of PLA degradable materials, coupled with lead-free and solder-free inner structures, and modularized and fully automated design, as well as the aesthetics of simple, rounded and hand-held shape, and the creative integration of the concepts of user detachable and biodegradable, Cyclo is ahead of the industry to achieve the balance of portability, artistry and recyclability for the users in advance.
While these two award-winning products are just a small microcosm of ICCPP ODM+'s human-centered, and user-first design philosophy. At ICCPP, we believe that design is not just about aesthetics, but should also keep upgrading user experience, meeting user needs and creating a more meaningful connection between people, society and nature. In the future, ICCPP ODM+ will continue to be committed to continuous innovation, to lead the design trend, to create more and more exciting and premium e-cigarette product solutions, and to bring a healthier and happier e-atomized life to vaping enthusiasts around the world.
For more information, please refer to: https://www.iccpp.com/
WARNING: This product contains nicotine which is a highly addictive substance.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230904756304/en/
Contact information
Media:
Carol, carol@iccpp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Landmark Global Galderma Survey Shows 9 out of 10 People Are Affected by Skin Quality Concerns7.7.2026 08:00:00 EEST | Press release
Galderma (SWX:GALD) has unveiled results from the world’s most extensive skin quality profiling survey, finding that skin quality concerns are widespread, can impact emotional wellbeing and, while differing based on the individual, are often similar among people alike in age, lifestyle, and environment.1 These results underscore the need for effective solutions that can be tailored to a wide variety of skin quality concerns. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706426842/en/ Key findings:1 Nine out of ten people globally are affected by skin quality concerns, with each person experiencing an average of two concerns in the past month The most common concerns are fine lines and wrinkles (41%), dry skin (40%), and dull skin (37%), most frequently affecting the face Skin quality impacts quality of life for 85% of people, with more than one in three reporting feelings of self-consciousness, insecurity or anxiety Skin
Morinaga Milk Achieves Self-Affirmed GRAS Status for LAC-Living+™, Expanding U.S. Opportunities for Its Postbiotic Ingredient7.7.2026 05:00:00 EEST | Press release
Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy and functional ingredient company, today announced that it has achieved self-affirmed GRAS (Generally Recognized As Safe) status in the United States for LAC-Living+™ (L. helveticus MCC1848), its proprietary postbiotic ingredient. This milestone expands the commercial availability of LAC-Living+ in the U.S. market and enables its use in dietary supplements, functional foods, and beverages, supporting the development of products designed to address growing consumer demand for health and well-being solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706806943/en/ Growing Interest in Postbiotics and Mental Well-Being Consumer interest in proactive health management has expanded significantly in recent years, alongside increasing awareness of the connection between the gut and the brain, commonly referred to as the gut–brain axis. As a result, the g
Access Advance Welcomes New Licensors to the Video Distribution Patent Pool7.7.2026 03:00:00 EEST | Press release
Access Advance LLC today announced that Sharp, M&K Holdings, Tagivan and 9 other patent owners who own substantial video codec patent portfolios that cover the core technologies behind video decoding, processing, and streaming media delivery, have joined the Video Distribution Patent Pool (VDP Pool) in the first half of 2026. "The addition of all of these new Licensors’ patent portfolios is a real win for both the VDP Pool and our many existing and future Licensees,” said Peter Moller, CEO of Access Advance. “These companies have broad and deep patent portfolios and further enhance the program’s market leading position in resolving the licensing issues around the use of modern video codecs across all the diverse business models of internet video streaming.” The following patent holders have joined the VDP Pool as Licensors in the first half of 2026: Digital Insights Inc. Hanbat National University Industry-Academic Cooperation Foundation Hanwha Vision Co., Ltd. Industry-Academy Coopera
Real Chemistry Announces New Asia Pacific Hub with Acquisition of Spurwing Communications in Singapore7.7.2026 02:00:00 EEST | Press release
Real Chemistry, a global leader in AI- and insights-driven healthcare communications, today announced the acquisition of Spurwing Communications, establishing the company’s first Asia Pacific (APAC) strategic hub in Singapore. This milestone strengthens Real Chemistry’s global strategy and presence in APAC, enhancing its ability to support healthcare organizations. Combining deep market expertise with globally integrated capabilities across analytics, medical communications, advertising and strategic communications, the company is well positioned to deliver more connected, local insight-driven support — ultimately helping clients better reach and engage healthcare professionals, patients and caregivers across the region. “APAC is fast becoming one of the most dynamic and strategically important regions for healthcare innovation and access to life-improving therapies,” said Kath Harrison, Group President, International Growth at Real Chemistry. “By bringing Spurwing into Real Chemistry,
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 23:04:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Crinetics for $85.00 per share in cash, for a total equity value of approximately $10.0 billion, or approximately $8.8 billion net of estimated cash acquired. The transaction was unanimously approved by both the Vertex and Crinetics Boards of Directors and is anticipated to close in the third quarter of 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706876183/en/ Crinetics’ marketed medicine, PALSONIFY® (paltusotine), received approval from the U.S. Food and Drug Administration (FDA) in September 2025. PALSONIFY was recently approved by the European Medicines Agency (EMA) a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom